David A. Siegel Atai Life Sciences N.V. Transaction History

Two Sigma Advisers, LP

$43.8 Billion
Q2 2024

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Atai Life Sciences N.V. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 45,800 shares of ATAI stock, worth $52,211. This represents 0.0% of its overall portfolio holdings.

Number of Shares

45,800

Previous 20,900 119.14%

Holding current value

$52,211

Previous $41,000 46.34%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$1.27 - $2.6 $31,623 - $64,740	24,900 Added 119.14%	45,800 $60,000
Q1 2024 May 15, 2024	SELL	$1.5 - $2.19 $60,750 - $88,695	-40,500 Reduced 65.96%	20,900 $41,000
Q4 2023 Feb 14, 2024	SELL	$1.04 - $1.55 $47,944 - $71,455	-46,100 Reduced 42.88%	61,400 $86,000
Q3 2023 Nov 14, 2023	SELL	$1.27 - $2.28 $77,216 - $138,624	-60,800 Reduced 36.13%	107,500 $138,000
Q2 2023 Aug 14, 2023	SELL	$1.44 - $2.19 $423,072 - $643,422	-293,800 Reduced 63.58%	168,300 $289,000
Q1 2023 May 15, 2023	BUY	$1.17 - $2.7 $34,281 - $79,110	29,300 Added 6.77%	462,100 $836,000
Q4 2022 Feb 14, 2023	BUY	$2.38 - $3.55 $429,352 - $640,420	180,400 Added 71.47%	432,800 $1.15 Million
Q3 2022 Nov 14, 2022	BUY	$3.14 - $4.87 $176,468 - $273,694	56,200 Added 28.64%	252,400 $835,000
Q2 2022 Aug 15, 2022	BUY	$3.03 - $5.32 $349,965 - $614,460	115,500 Added 143.12%	196,200 $714,000
Q1 2022 May 16, 2022	BUY	$4.66 - $7.66 $90,404 - $148,604	19,400 Added 31.65%	80,700 $411,000
Q4 2021 Feb 14, 2022	BUY	$6.82 - $17.8 $418,066 - $1.09 Million	61,300 New	61,300 $468,000

Others Institutions Holding ATAI

# of Institutions

Shares Held

12.8M

Call Options Held

9.2K

Put Options Held

118K

View Full List

About ATAI Life Sciences N.V.

Ticker ATAI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 165,875,008
Market Cap $189M
Description
Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment o...

More about ATAI

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account